USPTO trademark

ALTAIRA

AllowedUSPTOWord markClass 1Class 5Class 42

"ALTAIRA" is a word mark owned by Nortiva Bio, Inc., filed at the USPTO on November 19, 2025. It has been allowed and covers classes 1, 5 and 42.

Get this data via the API
Official USPTO record
ALTAIRA trademark as filed
As filed with the USPTO
Status
Allowed
Since September 8, 2026
Filed
November 19, 2025
Registered
Not yet
Expires
Not recorded
Application no.
99505429
Registration no.
Not yet
Office
USPTO
United States Patent and Trademark Office
Mark type
Word mark
3 classes
Ownership

Who owns ALTAIRA

The owner and representative on file with the office.

Owner

Nortiva Bio, Inc.

Waltham, United States

Representative

Keith Toms

McCarter & English, LLP

Goods and services

What the mark covers

The products and services ALTAIRA is filed for, grouped by Nice class.

  • Excipients for use in the manufacture of pharmaceutical preparations; Chemical additives for use in the manufacture of pharmaceutical preparations; Active chemical ingredients for use in the manufacture of pharmaceuticals

  • Drug delivery agents in the form of capsules, pills, ingestible flexible stars, ingestible arm-and-hub delivery platforms contained in capsules, dissolvable films, and coatings that facilitate the delivery of pharmaceutical preparations; Drug delivery agents in the form of long-acting, extended release, or continuous release capsules, pills, ingestible flexible stars, ingestible arm-and-hub delivery platforms contained in capsules, dissolvable films, and coatings that facilitate the delivery of pharmaceutical preparations; Drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals; Pharmaceutical preparations for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Pharmaceutical preparations for the treatment of infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders; Pharmaceutical preparations for the treatment of organ rejection, namely, immunosuppressants; Pharmaceutical preparations for the treatment of schizophrenia, bipolar disorder, cardiovascular disease, cardiometabolic disease, addiction, malaria, infectious diseases, septic shock, hypotension; Antibiotics; Pharmaceutical preparations used in organ transplantation; Contraceptive preparations

  • Pharmaceutical research and development; Scientific research; Medical research; Providing medical and scientific research information in the field of pharmaceuticals and clinical trials; Research and development of technology in the field of drug delivery; Research and development of technology in the field of long-acting, extended release, and continuous release drug delivery agents; Research and development of technology that facilitate the delivery of pharmaceutical preparations in the field of capsules, pills, ingestible flexible stars, ingestible arm-and-hub delivery platforms contained in capsules, dissolvable films, and coatings; Pharmaceutical research in the field of drug delivery agents; Pharmaceutical research in the field of capsules, pills, ingestible flexible stars, dissolvable films, and coatings that facilitate the delivery of pharmaceutical preparations; Pharmaceutical research in the field of excipients and pharmaceutical formulation; Pharmaceutical research in the field of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Pharmaceutical research in the field of antibiotics, infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders; Pharmaceutical research in the field of schizophrenia, bipolar disorder, cardiovascular disease, cardiometabolic disease, addiction, malaria, infectious diseases, septic shock, hypotension; Medical and scientific research in the field of drug delivery agents; Medical and scientific research in the field of capsules, pills, ingestible flexible stars, dissolvable films, and coatings that facilitate the delivery of pharmaceutical preparations; Medical and scientific research in the field of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Medical and scientific research in the field of antibiotics, infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders; Medical and scientific research in the fields of organ rejection and immunosuppressants; Medical and scientific research in the field of excipients and pharmaceutical formulation; Medical and scientific research in the field of schizophrenia, bipolar disorder, cardiovascular disease, cardiometabolic disease, addiction, malaria, infectious diseases, septic shock, hypotension; Consulting services in the field of pharmaceutical research

History

What has happened so far

Steps recorded by the USPTO, newest first.

  1. Noa e-mailed - sou required from applicant
  2. Official gazette publication confirmation e-mailed
  3. Published for opposition
  4. Notification of notice of publication e-mailed
  5. Approved for pub - principal register
  6. Notification of examiners amendment e-mailed
  7. Examiner's amendment entered
  8. Examiners amendment e-mailed
  9. Examiners amendment -written
  10. Previous allowance count withdrawn

10 earlier steps on the official record.

FAQ

About ALTAIRA

Who owns the trademark "ALTAIRA"?

The USPTO trademark "ALTAIRA" (application 99505429) is owned by Nortiva Bio, Inc.

What is the status of "ALTAIRA"?

Its status at the USPTO is: allowed.

API

Get this data via the API

Everything on this page comes from the Signa API. Pull ALTAIRA and marks like it into your own product with one request.

  • GET/v1/trademarks/{id}

    The full record: owners, classes, dates and images

  • GET/v1/trademarks/{id}/events

    Every step in the office history

  • GET/v1/proceedings?trademark_id={id}

    Oppositions and cancellations against the mark

Get API keyView docs
GET /v1/trademarks/{id}
ID=tm_019d2b61-bc58-7723-988e-bcf36a543cac
curl https://api.signa.so/v1/trademarks/$ID \
  -H "Authorization: Bearer $SIGNA_API_KEY"
Response
{
  "id": "tm_019d2b61-bc58-7723-988e-bcf36a543cac",
  "object": "trademark",
  "mark_text": "ALTAIRA",
  "status": {
    "primary": "pending",
    "stage": "allowed"
  },
  "office_code": "US",
  "application_number": "99505429",
  "filing_date": "2025-11-19",
  "nice_classes": [
    1,
    5,
    42
  ],
  "owners": [
    {
      "name": "Nortiva Bio, Inc.",
      "entity_id": null
    }
  ]
}